SAGE Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -747.33% compared to Sage Therapeutics's net margin of -886.28%. Sage Therapeutics's return on equity of -63.59% beat Cytokinetics's return on equity of --.

Sage Therapeutics has a consensus price target of $8.05, signalling upside risk potential of 4.22%. On the other hand Cytokinetics has an analysts' consensus of $79.10 which suggests that it could grow by 78.31%. Given that Cytokinetics has higher upside potential than Sage Therapeutics, analysts believe Cytokinetics is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.817, which suggesting that the stock is 18.337% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.949, suggesting its less volatile than the S&P 500 by 5.057%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Cytokinetics quarterly revenues of $16.9M. Sage Therapeutics's net income of -$95.8M is higher than Cytokinetics's net income of -$150M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.37x versus 268.32x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Intra-Cellular Therapies has a net margin of -747.33% compared to Sage Therapeutics's net margin of -8.48%. Sage Therapeutics's return on equity of -63.59% beat Intra-Cellular Therapies's return on equity of -8.07%.

Sage Therapeutics has a consensus price target of $8.05, signalling upside risk potential of 4.22%. On the other hand Intra-Cellular Therapies has an analysts' consensus of $132.00 which suggests that it could grow by 0.56%. Given that Sage Therapeutics has higher upside potential than Intra-Cellular Therapies, analysts believe Sage Therapeutics is more attractive than Intra-Cellular Therapies.

Sage Therapeutics has a beta of 0.817, which suggesting that the stock is 18.337% less volatile than S&P 500. In comparison Intra-Cellular Therapies has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.512%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intra-Cellular Therapies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Intra-Cellular Therapies pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Intra-Cellular Therapies quarterly revenues of $199.2M. Sage Therapeutics's net income of -$95.8M is lower than Intra-Cellular Therapies's net income of -$16.9M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Intra-Cellular Therapies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.37x versus 19.89x for Intra-Cellular Therapies. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -747.33% compared to Sage Therapeutics's net margin of 15.24%. Sage Therapeutics's return on equity of -63.59% beat Johnson & Johnson's return on equity of 19.98%.

Sage Therapeutics has a consensus price target of $8.05, signalling upside risk potential of 4.22%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that Sage Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Sage Therapeutics is more attractive than Johnson & Johnson.

Sage Therapeutics has a beta of 0.817, which suggesting that the stock is 18.337% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. Sage Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Sage Therapeutics's net income of -$95.8M is lower than Johnson & Johnson's net income of $3.4B. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.37x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -747.33% compared to Sage Therapeutics's net margin of -117.16%. Sage Therapeutics's return on equity of -63.59% beat Moderna's return on equity of -29.09%.

Sage Therapeutics has a consensus price target of $8.05, signalling upside risk potential of 4.22%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than Sage Therapeutics, analysts believe Moderna is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.817, which suggesting that the stock is 18.337% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Moderna quarterly revenues of $956M. Sage Therapeutics's net income of -$95.8M is higher than Moderna's net income of -$1.1B. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.37x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.